10.44
0.13 (1.26%)
| Previous Close | 10.31 |
| Open | 10.50 |
| Volume | 4,680,857 |
| Avg. Volume (3M) | 4,654,806 |
| Market Cap | 5,163,770,368 |
| Price / Earnings (TTM) | 15.35 |
| Price / Earnings (Forward) | 12.36 |
| Price / Sales | 1.18 |
| Price / Book | 0.850 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Profit Margin | 7.61% |
| Operating Margin (TTM) | 1.37% |
| Diluted EPS (TTM) | 0.680 |
| Quarterly Revenue Growth (YOY) | -1.40% |
| Total Debt/Equity (MRQ) | 72.90% |
| Current Ratio (MRQ) | 2.44 |
| Operating Cash Flow (TTM) | 541.00 M |
| Levered Free Cash Flow (TTM) | 946.75 M |
| Return on Assets (TTM) | 1.19% |
| Return on Equity (TTM) | 5.49% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | Elanco Animal Health Incorporat | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.25 |
|
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 0.88% |
| % Held by Institutions | 100.87% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 19.00 (Barclays, 81.99%) | Buy |
| Median | 13.00 (24.52%) | |
| Low | 12.00 (Piper Sandler, 14.94%) | Hold |
| Average | 14.80 (41.76%) | |
| Total | 3 Buy, 2 Hold | |
| Avg. Price @ Call | 10.58 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 14 Apr 2025 | 13.00 (24.52%) | Buy | 8.68 |
| 26 Feb 2025 | 15.00 (43.68%) | Buy | 11.13 | |
| Piper Sandler | 06 Mar 2025 | 12.00 (14.94%) | Hold | 10.83 |
| Barclays | 26 Feb 2025 | 19.00 (81.99%) | Buy | 11.13 |
| Morgan Stanley | 26 Feb 2025 | 13.00 (24.52%) | Hold | 11.13 |
| 29 Jan 2025 | 14.00 (34.10%) | Hold | 12.29 | |
| UBS | 26 Feb 2025 | 17.00 (62.84%) | Buy | 11.13 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |